Introduction {#Sec1}
============

Primary central nervous system (CNS) tumors occur at an incidence of 16.5 cases/100,000 person-years, of which approximately 27% represent children less than 19 years old (CBTRUS [@CR20]). Primary CNS tumors occur more in men (3.7/100,000 person-years) than in women (2.6/100,000-person-years; GLOBOCAN [@CR57]; Parkin et al. [@CR115]) and are composed of a diverse set of histological and biochemical features, each associated with its own morbidity and mortality despite multimodality treatment with surgery, radiation, chemotherapy, and biologic approaches. In the USA, the mortality rates for primary malignant brain tumors ranges from 3.7--5.6 per 100,000 with 25--29% 5 and 10-year survival, respectively, according to American Cancer Society statistics (<http://www.cancer.org/statistics/>). In terms of epidemiologic etiologies of primary brain tumors, many potential risk factors have been studied including genetic susceptibility (genetic syndromes or gene-specific polymorphisms), radiation exposure (ionizing and non-ionizing electromagnetic fields), neuro-carcinogens, allergic diseases, and viral infections (Wrensch et al. [@CR154]; Bondy et al. [@CR14]). Since viral infections have been associated with other systemic human malignancies including hepatitis B/C (hepatocellular carcinoma), Epstein Barr virus (EBV; B+T cell lymphoma, post-transplant lymphoproliferative disease, leiomyosarcoma, nasopharyngeal carcinoma), human papillomavirus (cervical carcinoma), human herpesvirus-8 (HHV-8; Kaposi sarcoma), and human T cell lymphotropic virus type 1 (T cell leukemia), it is not unreasonable to hypothesize a role for viral infections in CNS malignancies (Liao [@CR91]). With regards to viral etiologies of primary CNS tumors, the polyomavirus and herpesvirus families have been among the most widely studied. Over the past few decades, the interest in the polyomavirus family of viruses has grown in parallel to both the viruses' association with human brain tumors and oncogenecity in experimental animals (Croul et al. [@CR34]; White et al. [@CR151]; Ahsan and Shah [@CR2]; Jiang et al. [@CR75]). Among the members of the polyomavirus family, the three that have been detected most widely in both pediatric and adult histological subtypes of primary CNS brain tumors are the JC virus (JCV), BK virus (BKV), and Simian vacuolating virus 40 (SV40; Croul et al. [@CR34]; White et al. [@CR151]; Barbanti-Brodano et al. [@CR8]; Lee and Langhoff [@CR90]). The more recently discovered members of the polyomavirus family (KI, WU, and MC) have yet to be studied in association with human brain tumors (zur Hausen [@CR162]; Dalianis et al. [@CR36]). The polyomavirus family is of considerable interest in its potential role in neuro-oncogenesis since it has been shown to induce brain tumors in animal models (Rollison et al. [@CR126]; Rollison [@CR125]). The herpesvirus family is a functionally and structurally diverse group consisting of eight known human variants (herpes simplex 1-2; varicella zoster virus, Epstein Barr, human cytomegalovirus, human herpesviruses 6, 7, and 8) and has been associated with a number of human diseases (Arvin et al. [@CR4]). Since many of the herpesviruses can establish lifelong latency in the CNS, whereby only a limited number of viral genes are expressed without production of progeny virions and lytic infection, it is plausible to hypothesize that herpesviruses, among others, may play a role in CNS neuro-oncogenesis. In this comprehensive review of chronic viral infections and primary CNS malignancy, we hope to summarize the numerous published results both in support and in contradictory to the role of chronic viral infection in human primary CNS malignancies. Furthermore, we would like to address potential neuro-oncologic molecular mechanisms of disease related to the specific viruses reported in CNS tumors. Finally, we hope to address the many controversies and propose future research directions that promote a greater understanding of neurovirology in the area of neuro-oncology research.

Detection of human herpesviruses in primary CNS malignancy {#Sec2}
==========================================================

Herpes simplex 1, 2 {#Sec3}
-------------------

Human herpes simplex viruses 1 and 2 (HSV-1/2), members of the alphaherpesvirus family of DNA viruses, are between 152--154 kbp (McGeoch et al. [@CR100]; Dolan et al. [@CR46]). HSV-1/2 infection is most notable for its role in CNS encephalitis (Kimberlin [@CR81]). Surprisingly, most of the data on HSV-1/2 infection and primary CNS tumors comes from serological IgG antibody studies by enzyme-linked immunosorbent assay as summarized in Table [1](#Tab1){ref-type="table"}. Between 79.6--82% of patients with glioblastoma multiforme (GBM) were seropositive for HSV-1/2 compared with 58--72% of other tumor brain tumor types and 76.1--79.6% of non-tumor controls (Wrensch et al. [@CR153], 2005). A high percentage of seropositivity (86%) has also been reported in a series of 72 primary CNS glioma, meningioma, and acoustic schwanomma (Poltermann et al. [@CR119]). Viral nucleic acid detection of HSV-1/2 by real-time quantitative PCR revealed 2.8% positivity in low-grade pilocytic astrocytomas (*N* = 35; Neves et al. [@CR109]). Only a small number of primary CNS tumors have been tested for HSV-1/2 by in situ hybridization (ISH), and all have been negative (Cobbs et al. [@CR28]). To our knowledge, there has not been a detailed immunohistochemistry (IHC) analysis performed on a series of primary CNS tumors to assess for HSV-1/2 viral antigen. Table 1Detection of human herpesviruses in primary central nervous system malignancyHerpesvirus subtypeTumor histology subtypesSerum viral IgG antibody detection (ELISA)Viral nucleic acid detection (PCR, nPCR, qPCR, ISH)Viral protein detection (IHC)ReferenceHHV 1-2 (HSV1/2)GBM (*N* = 45), other glial subtypes (*N* = 43)37/45 GBM+ 25/43 other glial subtypes+ 90/113 non-tumor controls+NPNPWrensch et al. [@CR153]GBM (*N* = 113), other brain tumor subtypes (*N* = 111)90/113 GBM+ 79/111 other brain tumor subtypes +, 217/285 non-tumor controls +NPNPWrensch et al. [@CR155]Pilocytic astrocytoma (*N* = 35)NP1/35 Pilocytic astrocytoma +, 2/10 non-tumor control+ by qPCRNPNeves et al. [@CR109]Glial tumors (*N* = 35), meningiomas (*N* = 31) acoustic schwanommas (*N* = 6)62/72 Total tumors+NPNPPoltermann et al. [@CR119]GBM (*N* = 3) diffuse fibrillary astrocytoma (*N* = 2)NP0/3 GBM+, 0/2 diffuse fibrillary astrocytoma+, 0/3 normal brain+ by ISHNPCobbs et al. [@CR28]HHV-3 (VZV)Glial tumors (*N* = 78)56/78 Glial tumors+, 73/89 non-brain tumor controls+NPNPWrensch et al. [@CR152]GBM(*N* = 46) other brain tumor subtypes (*N* = 68)38/46 GBM+, 63/68 other brain tumor subtypes+, 137/139 non-brain tumor controls+NPNPWrensch et al. [@CR153]GBM (*N* = 115), other brain tumor subtypes (*N* = 114)109/115 GBM+, 110/114 other brain tumor subtypes+, 282/289 non-brain tumor control +NPNPWrensch et al. [@CR155]Pilocytic astrocytoma (*N* = 35)NP2/35 Pilocytic Astrocytoma+, 0/10 Non-Tumor Control+ by qPCRNPNeves et al. [@CR109]Glial tumors (*N* = 35), meningiomas (*N* = 31) acoustic schwanommas (*N* = 6)66/72 Total tumors+NPNPPoltermann et al. [@CR119]HHV-4 (EBV)GBM(*N* = 48) other brain tumor subtypes (*N* = 69)41/48 GBM+, 62/69 other brain Ttumor subtypes+, 139/151 non-brain tumor control+NPNPWrensch et al. [@CR153]GBM (*N* = 115), other brain tumor subtypes (*N* = 113)106/115 GBM+, 105/113 other brain tumor subtypes+, 266/283 non-brain tumor control +NPNPWrensch et al. [@CR155]Pilocytic astrocytoma (*N* = 35)NP9/35 Pilocytic Astrocytoma +, 7/9 Non-Tumor Control+ by qPCRNPNeves et al. [@CR109]Glial tumors (*N* = 35), meningiomas (*N* = 31) acoustic schwanommas (*N* = 6)64/72 Total tumors+NPNPPoltermann et al. [@CR119]HHV-5 (CMV)GBM, anaplastic astrocytoma, diffuse fibrillary astrocytoma, meningiomaNP7/9GBM+ (nPCR);12/12 GBM+,4/4 diffuse fibrillary astrocytoma+, 0/5 meningioma+,0/8 normal brain, 0/9 other neurological diseases (ISH)38/38 GBM+, 1/1 anaplastic astrocytoma, 6/6 diffuse fibrillary astrocytoma+, 0/9 meningioma+,0/6 normal brain, 0/9 other neurological diseases (IHC using 3 antibodies)Cobbs et al. [@CR28]GBM, primary GBM cell culturePeripheral blood samplesNP29/68 GBM+, 22/34 primary GBM cell culture+ (nPCR with 2 primers);16/16 GBM+ (ISH);16/20 peripheral blood+ , 0/17 non-tumor controls+ (PCR)72/78 GBM+, 16/16 primary GBM cell cultures+ ( IHC using two antibodies)Mitchell et al. [@CR106]GBM (*N* = 21), anaplastic astrocytoma (*N* = 12), low-grade glioma (*N* = 17)NPNP21/21GBM+,9/12 anaplastic astrocytoma+,14/17 low-grade glioma+,0/6 non-brain tumor controls+ (IHC)Scheurer et al. [@CR130]Glial tumors (*N* = 35), meningiomas (*N* = 31) acoustic schwanommas (*N* = 6)46/72 Total Tumors+0/72 Total tumors+ (nPCR with two primers)0/72 Total tumors+ (IHC using 2 antibodies)Poltermann et al. [@CR119]GBM (*N* = 8), diffuse fibrillary astrocytoma (*N* = 3), anaplastic astrocytoma (*N* = 6), oligodendrioglioma (*N* = 2), ependymoma (*N* = 3)NP0/22 Total tumors+, 0/4 normal brain+, 0/24 other neurological diseases+ (nPCR, ISH)0/22 Total tumors+, 0/4 normal brain+, 0/24 other neurological diseases+ (IHC)Lau et al. [@CR88]GBM (*N* = 97), ependymoma (*N* = 15), oligodendroglioma (*N* = 20)NP7/97 GBM+, 0/15 ependymoma+, 0/20 oligodendroglioma+ (ISH)9/97 GBM+ ,0/15 ependymoma+, 0/20 oligodendroglioma+ (ISH)Sabatier et al. [@CR128]GBM (*N* = 37) other brain tumor subtypes (*N* = 39)24/37 GBM+, 20/39 other brain tumor subtypes+, 54/94 non-brain tumor control+NPNPWrensch et al. [@CR153]GBM (*N* = 115), other brain tumor subtypes (*N* = 113)71/115 GBM+, 61/113 other brain tumor subtypes+, 163/287 non-brain tumor control +NPNPWrensch et al. [@CR155]HHV-6Extensive series of glial and neuronal Tumors (*N* = 98)NP4/36 Meningioma+,1/18 GBM+, 3/5 ependymoma+ (nPCR)Chan et al. [@CR21]Glial and neuronal tumor subtypes (*N* = 37)NP6/37 Total tumors+ (nPCR)NPLuppi et al. [@CR94]Extensive series of glial and neuronal tumors (*N* = 118)90/115 Total tumors+, 106/150 non-tumor controls+14/31 GBM+, 2/2 neuroblastoma+, 9/35 meningioma+, 1/2 ependymoma+, 2/6 astrocytoma+, 15/39 other brain tumor subtypes+ (nPCR)4/10 Tumors+ (IHC)Cuomo et al. [@CR35]Pediatric pilocytic astrocytoma (*N* = 35)NP0/35 Pilocytic astrocytoma+, 0/10 non-tumor control+ by qPCRNPNeves et al. [@CR109]Extensive series of pediatric glial and neuronal tumors (*N* = 150)NP141/240 Total tumors+, 18/64 non-brain tumor controls+ (nPCR with two primers); 83/150 total tumors+, 10/32 non-brain tumor controls+ (ISH)50/124 Total tumors+, 6/32 non-brain tumor controls+ (IHC)Crawford et al. [@CR32]Extensive series of pediatric glial and neuronal tumors (*N* = 282)NP14/30 Total tumors+, 0/25 non-tumor controls+ (nPCR); 106/224 total tumors+, 0/25 non-tumor controls+ (ISH)150/559 Total tumors+, 0/25 non-tumor controls+ (IHC with two antibodies)Crawford et al. [@CR33]GBM (*N* = 23), anaplastic astrocytoma (*N* = 3), anaplastic oligodendroglioma (*N* = 2), medulloblastoma (*N* = 12)NP0/41 Total tumors+ (by digital karyotyping)NPDuncan et al. [@CR47]HHV-7Extensive series of glial and neuronal tumors (*N* = 98)NP5/36 Meningioma+, 3/18 GBM+, 1/5 ependymoma+, 1/8 schwannoma+, 2/16 other astrocytoma+, 2/5 other brain tumors+ (nPCR)Chan et al. [@CR21]Pediatric pilocytic astrocytoma (*N* = 35)NP1/35 Pilocytic astrocytoma+, 0/6 non-tumor control+ by qPCRNPNeves et al. [@CR109]HHV-8(KSV)Pediatric pilocytic astrocytoma (*N* = 35)NP0/35 Pilocytic astrocytoma+, 0/6 non-tumor control+ by qPCRNPNeves et al. [@CR109]Abbreviations: *NP* not performed, *ELISA* enzyme-linked immunosorbent assay, *PCR* polymerase chain reaction, *nPCR* nested polymerase chain reaction, *qPCR* real-time quantitative polymerase chain reaction, *ISH* in situ hybridization, *IHC* immunohistochemistry, *GBM* glioblastoma multiforme

Varicella zoster virus {#Sec4}
----------------------

Varicella zoster virus (VZV), another member of the alphaherpesvirus family, is smaller in size than HSV-1/2 and exhibits neuronal latency (Davison and Scott [@CR37]). VZV DNA has been detected in 5.7% of pilocytic astrocytoma (2/35) compared with 0/10 non-tumor control brain and without IHC correlate (Table [1](#Tab1){ref-type="table"}). The more interesting data on the role of VZV and primary CNS tumors comes from epidemiologic studies comparing the frequency of serum IgG positivity in GBM, other brain tumor subtypes, and non-brain tumor controls. Wrensch et al. first demonstrated an inverse correlation between VZV IgG positivity in brain tumors (56/78) and non-tumor controls (73/89) (Wrensch et al. [@CR152]). The observed findings in GBM were reproduced in a subsequent study and revealed 38/46 anti-VZV IgG positive versus 137/139 non-brain tumor control sera (Wrensch et al. [@CR153]). A third larger study revealed no changes in the degree of anti-VZV IgG positivity between GBM and non-tumor sera (109/115 vs. 282/289), however when stratifying based on viral titer quartile, the inverse relationship was maintained (Wrensch et al. [@CR155]). While the authors mention that these findings could be related to the exclusion of patients on high-dose corticosteroids, the trends are reproducible and are worthy of a larger multi-institutional analysis to explore the possibility of a "neuroprotective effect" of VZV immunoglobulin detection in GBM.

Epstein Barr Virus {#Sec5}
------------------

EBV, a member of the gamma herpesvirus family, is present in greater than 90% of the population and is characterized by its persistence largely in lymphocytes (Volpi [@CR146]). EBV has been detected in greater than 95% of primary CNS lymphoma in HIV-related disease and 5% of CNS lymphoma in immunocompetent hosts (Gulley [@CR59]). Seropositivity for EBV is high in sera of patients with GBM (85--92%), other CNS tumor subtypes (90--93%), and non-tumor control sera (92--94%; Wrensch et al. [@CR153]; Wrensch et al. [@CR155]; Poltermann et al. [@CR119]). Interestingly, Neves et al. reported 9/35 EBV-positive pilocytic astrocytomas by quantitative PCR (their highest for any herpesvirus tested), however seven of nine normal cerebellum were also were positive by PCR (Neves et al. [@CR109]; Table [1](#Tab1){ref-type="table"}). Like HSV-1/2, there are no published reports on the frequency of EBV viral antigens in non-CNS lymphoma tumors by IHC.

Human cytomegalovirus {#Sec6}
---------------------

Human cytomegalovirus (CMV), a member of the betaherpesvirus family, has been the most studied and perhaps the most controversial of all the herpesviruses associated with primary CNS tumors (Miller [@CR104]). In terms of CMV IgG seropositivity in patients with primary CNS tumors, there has been a slight non-significant increase in positivity among patients with GBM (62--66%) compared to sera from other CNS malignancies (51--54%) or non-tumor control sera (57%) (Wrensch et al. [@CR153]; [@CR155]). Much of the published data in support of a role for CMV in CNS tumorigenesis comes from the detection of viral nucleic acids by PCR and ISH and proteins by IHC (Table [1](#Tab1){ref-type="table"}). Cobbs et al. first reported a strong association between CMV and GBM (Cobbs et al. [@CR28]). Using nested PCR with primers for the UL55 glycoprotein B gene, they reported positivity in 7/9 GBMs. ISH was used to confirm PCR findings with both whole-genome CMV primers (4/4 GBM, 2/2 diffuse fibrillary astrocytoma) and immediate early gene CMV primers (8/8 GBM, 2/2 diffuse fibrillary astrocytoma). CMV was not detected in normal control brain by PCR or ISH in this study (Cobbs et al. [@CR28]). The strong association of CMV and GBM was further demonstrated by IHC using IEI-72 immediate early antibody (22/22), p52/76 immediate early/early antigen antibody (8/8), and pp65 tegument protein antibody (8/8; Cobbs et al. [@CR28]). Similar IHC results were observed in other glial tumor subtypes (6/6 diffuse fibrillary astrocytoma, 1/1 anaplastic astrocytoma), but not in non-glial tumors (0/9 meningioma), non-tumor brain (0/6), or brain from other neurological diseases (0/9; Cobbs et al. [@CR28]). On the contrary, Sabatier et al. reported that less than 10% of GBMs in their French series were positive for CMV by either ISH (7/97) or IHC (9/97; Sabatier et al. [@CR128]). This study was followed by two other studies that failed to detect CMV in a series of 22 (Lau et al. [@CR88]) or 72 (Poltermann et al. [@CR119]) GBMs by PCR, ISH, or IHC using two different antibodies. More recently, two groups have reported widespread detection of CMV in GBM using similar techniques described by Cobbs et al. (Mitchell et al. [@CR106]; Scheurer et al. [@CR130]). Scheurer et al. reported strong positivity for CMV by IHC in GBM (21/21), anaplastic astrocytoma (9/12), and low-grade astrocytoma (14/17) compared with non-tumor brain controls (0/6; Scheurer et al. [@CR130]). Mitchell et al. reported strong positivity of GBMs by nested PCR (29/68), ISH (16/16), and IHC (72/78) compared with non-tumor controls. Additionally, Mitchell et al. reported similar finding in short-term primary glioblastoma cultures (23/34 PCR+, 16/16 IHC+) and in peripheral blood of patients with GBM (16/20) compared with controls (Mitchell et al. [@CR106]). It has been suggested that tissue processing, amount of template DNA used for PCR, and concentrations and conditions of IHC methodology may all be possible explanations for discrepancies among researchers (Scheurer et al. [@CR129]).

Human Herpesvirus-6 {#Sec7}
-------------------

Human herpesvirus-6 (HHV-6) is a member of the betaherpesvirus and exists as two variants A (HHV6-A) and B (HHV6-B; Caserta [@CR19]; De Bolle et al. [@CR38]). HHV-6 B is the causative agent of the common viral exanthematous disease roseola infantum (Yamanishi et al. [@CR157]), while HHV-6 A has been shown to have more neurotropic features (Hall et al. [@CR61]), including altering cytokine synthesis in astrocyte cell lines (Yoshikawa et al. [@CR159]). Initially discovered as a B cell lymphotropic virus, chromosomally integrated forms of HHV-6 have been recognized and may play a role in disease pathogenesis (Clark and Ward [@CR27]; Hall et al. [@CR62]). In terms of HHV-6 seroprevalence, greater than 90% of humans become seropositive within the first year of life (Okuno et al. [@CR112]; Hall et al. [@CR60]; Zerr et al. [@CR161]). Regarding primary CNS tumors, one study revealed significant differences in seroreactivity measured by indirect immunofluorescence in brain tumor patients (90/115) versus controls (106/150) (Cuomo et al. [@CR35]). The same study reported HHV-6 PCR positivity in 45% of GBMs (14/31) and 4/10 tumors expressed early HHV-6 viral antigen p41 detected by IHC (Table [1](#Tab1){ref-type="table"}). Others have reported between 14--16% of brain tumor samples were positive by nested PCR (Luppi et al. [@CR94]; Chan et al. [@CR21]). Most recently, we reported the detection of HHV-6 in a large series of previously untreated fresh frozen and paraffin-embedded pediatric primary CNS brain tumors by nested PCR, ISH, and IHC (Crawford et al. [@CR32]). HHV-6 variants were detected in tumors by nested PCR (59%), ISH (55%), and IHC (40%), significantly more than age-matched non-tumor brain. Interestingly, the low-grade gliomas showed significantly higher immunopositivity for the HHV-6 glycoprotein gp116/64/54 than higher-grade glial and non-glial tumor subtypes. We reported similar frequencies of HHV-6 positivity by nested PCR (47%), ISH (47%), and ICH (27%) in a large adult cohort of paraffin-embedded brain tumors (Crawford et al. [@CR33]). In both studies, the glial tumors were significantly more positive by IHC than non-glial tumors, and there was a predominance of HHV6-A confirmed by sequence analysis. The major differences between the adult and pediatric studies include the lack of association between tumor grade and IHC positivity in adults and the lack of detection of virus in a small number of adult non-tumor brain (Crawford et al. [@CR32][@CR33]). Contrary to our findings, Neves et al. reported no detectable HHV-6 in a series of non-paraffin-embedded normal cerebellum and pilocytic astrocytomas by quantitative PCR (Neves et al. [@CR109]). Since few of our samples were primary PCR-positive for HHV-6, it is likely that CNS tumors harbor virus at very low levels. Although the concept of a neurotropic viral infection obtained during early childhood as a potential modifier in CNS neuro-oncogenesis is tempting, more work still needs to be done to determine what role, if any, HHV-6 plays in primary CNS brain tumors.

Human herpesvirus-7 and human herpesvirus-8 {#Sec8}
-------------------------------------------

Human herpesvirus-7 (HHV-7) and human herpesvirus-8 (HHV-8) are relatively newly described herpesviruses with little published findings with regard to CNS malignancy. No seroprevalence data in conjunction with CNS tumors has been published to date on either virus. HHV-7 has been detected by PCR in 3% (1/35) to 16% (14/88) of CNS tumors (Chan et al. [@CR21]; Neves et al. [@CR109]; Table [1](#Tab1){ref-type="table"}). HHV-8 was not detected by PCR in a series of 35 pediatric pilocytic astrocytomas (Neves et al. [@CR109]). More widespread serological and biological studies are necessary to determine whether HHV-7 and HHV-8 play a role in CNS brain tumors.

Detection of polyomaviruses in primary CNS malignancies {#Sec9}
=======================================================

JC virus {#Sec10}
--------

The JCV was first discovered in 1971, isolated from the brain of a patient with progressive multifocal leukoencephalopathy, a degenerative, demyelinating disease (Padgett et al. [@CR114]). Since then, the JCV has been found experimentally to be oncogenic in both animal models and human-derived cell lines (extensively reviewed in Croul et al. [@CR34]; White et al. [@CR151]; Barbanti-Brodano et al. [@CR8]; Maginnis and Atwood [@CR95]; Ahsan and Shah [@CR2]; Jiang et al. [@CR75]). The seroprevalence of JCV in the human population is estimated to range from around 19--50% and increases with age (Knowles et al. [@CR83]).

A summary of the experimental approaches used in detection of JCV in human primary CNS tumors is summarized in Table [2](#Tab2){ref-type="table"}. Researchers have largely employed PCR and Southern blot hybridization techniques for sensitive detection of JCV genome and IHC for the viral proteins. In the case of JCV, IHC has been used to detect both large T antigen (TAg) and agnoprotein, both involved in JCV oncogenesis. As summarized in Table [2](#Tab2){ref-type="table"}, JCV has been detected in a wide variety of diverse CNS tumor subtypes. Of all studies which report JCV positivity by PCR, only oligodendroglioma (13/18), astrocytoma (14/26), ependymoma (5/18), GBM (19/34), and medulloblastoma (22/39) were studied in sufficient quantity to have significance. Of all the studies, only four were done in pediatric CNS tumors (Boldorini et al. [@CR12]; Krynska et al. [@CR87]; Okamoto et al. [@CR111]; Vasishta et al. [@CR145]). The percentage of JCV IHC positivity is roughly half of that reported by PCR for each tumor subtype across the majority of both pediatric and adult studies employing both technologies. In the case of medulloblastoma, several researchers have failed to detect JCV by both PCR and IHC (Hayashi et al. [@CR65]; Kim et al. [@CR80]; Okamoto et al. [@CR111]; Vasishta et al. [@CR145]). The differences between the groups is not entirely clear and may be related to the sensitivities of the PCR methodologies used, as JCV DNA fragments (and not viral antigens) have been recently reported in a small series of normal human brain (Perez-Liz et al. [@CR116]). Table 2Detection of polyomaviruses in primary central nervous system malignancyDetected/sampled (%)Detection methodDNAProteinsDNAProteinsReferenceJC virusGangliocytoma0/10/1nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]Choroid plexus papilloma1/5 (20)1/5 (20)PCR, SBIHC (TAg, Agno)Okamoto et al. [@CR111]Pilocytic astrocytoma4/5 (80)1/5 (20)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]0/70/7PCR, SBIHC (TAg, Agno)Okamoto et al. [@CR111]Subependymoma1/1 (100)1/1 (100)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]Pleomorphic xanthoastrocytoma1/1 (100)--nPCRIHC (TAg)Boldorini et al. [@CR12]Oligodendroglioma4/7 (57)--PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]13/18 (72)8/18 (44), 10/18 (56)PCR, SBIHC (TAg, Agno)Del Valle et al. [@CR44]1/2 (50)1/2 (50)nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]1/5 (20)0/5nPCRIHC (TAg)Caldarelli-Stefano et al. [@CR17]Astrocytoma (all subtypes)4/10 (40)1/10 (10)nPCRIHC (TAg)Caldarelli-Stefano et al. [@CR17]1/3 (33)1/3 (33)nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]10/16 (63)7/16 (44)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]Ependyoma5/6 (83)4/6 (67)PCR, SBIHC (TAg)Del Valle et al. [@CR42]5/18 (28)4/18 (22), 3/18 (17)PCR, SBIHC (TAg, Agno)Okamoto et al. [@CR111]0/20/2nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]1/5 (20)0/5nPCRIHC (TAg)Caldarelli-Stefano et al. [@CR17]Oligoastrocytoma5/8 (63)2/8 (25)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]1/1 (100)1/1 (100)PCRIPPt (TAg)Rencic et al. [@CR123]Anaplastic oligodendroglioma2/3 (67)2/3 (67)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]Anaplastic astrocytoma3/4 (75)0/4PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]Anaplastic oligodendroglioma2/3 (67)2/3 (67)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]2/2 (100)2/2 (100), 1/2 (50)PCR, SBIHC (TAg, Agno)Del Valle et al. [@CR44]Gliomatosis cerebri1/1 (100)1/1 (100)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]GBM12/21 (57)5/21 (24)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]1/1 (100)1/1 (100)PCR, SBIHC (TAg)Del Valle et al. [@CR41]7/13 (54)7/13 (54)nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]1/1 (100)1/1 (100), 1/1 (100)PCRIHC (TAg, Agno)Pina-Oviedo et al. [@CR117]Medulloblastoma11/16 (68)9/16 (56), 11/16 (68)PCRIHC (TAg, Agno)Del Valle et al. [@CR45]0/80/8PCR, SBIHC (TAg)Hayashi et al. [@CR65]11/23 (48)4/23 (17)PCR, SBIHC (TAg)Krynska et al. [@CR87]0/150/15PCR, SBIHC (TAg)Kim et al. [@CR80]--0/22--IHC (TAg, Agno)Vasishta et al. [@CR145]0/320/32PCR, SBIHC (TAg)Okamoto et al. [@CR111]Pineoblastoma0/10/1nPCR, PCRIHC (TAg)Boldorini et al. [@CR13]Gliosarcoma1/1 (100)1/1 (100)PCR, SBIHC (TAg)Del Valle et al. [@CR42], [@CR43]sPNET0/50/5PCR, SBIHC (TAg)Kim et al. [@CR80]BK virusChoroid plexus papilloma6/6 (100)--PCR, SBMartini et al. [@CR98]Oligodendroglioma1/1 (100)--SBDorries et al. [@CR48]7/9 (78)--PCR, SBMartini et al. [@CR98]Astrocytoma0/3--SBDorries et al. [@CR48]16/17 (94)1/1 (100)PCR, SBRT-PCR (TAg)Martini et al. [@CR98]Ependymoma10/11 (91)--PCR, SBMartini et al. [@CR98]2/3 (60)--PCR, SBNegrini et al. [@CR108]Medulloblastoma0/150/15PCR, SBIHC (TAg)Kim et al. [@CR80]GBM0/75--PCRArthur et al. [@CR3]2/5 (40)--SBDorries et al. [@CR48]28/30 (93)7/9 (78)PCR, SBRT-PCR (TAg)Martini et al. [@CR98]Brain tumor (mixed subtypes)19/74 (26)--SBCorallini et al. [@CR31]50/58 (86)--PCR, SBDe Mattei et al. [@CR39]Meningioma5/6 (83)--SBDorries et al. [@CR48]4/7 (57)--PCR, SBMartini et al. [@CR98]Neurinoma3/3 (100)--SBDorries et al. [@CR48]sPNET0/50/5PCR, SBIHC (TAg)Kim et al. [@CR80]Simian virus 40Choroid plexus papilloma5/6 (83)--PCR, SBMartini et al. [@CR98]10/20 (50)--PCR, IHC (TAg)Bergsagel et al. [@CR10]6/16 (38)--PCR, SBHuang et al. [@CR70]--1/39 (3)IHC (TAg)Tabuchi et al. [@CR141], [@CR142]10/13 (77)--PCRLednicky et al. [@CR89]1/14 (7.1)0/7PCRRT-PCREngels et al. [@CR50]Subependymoma1/2 (50)--PCRWeggen et al. [@CR149]Oligodendroglioma3/12 (25)--PCR, SBHuang et al. [@CR70]0/9--PCR, SBMartini et al. [@CR98]1/3 (33)--SBKrieg et al. [@CR86]Astrocytoma (all subtypes)8/17 (47)--PCR, SBMartini et al. [@CR98]0/3--SBKrieg et al. [@CR86]22/50 (44)--PCR, SBHuang et al. [@CR70]1/8 (13)--SBKrieg et al. [@CR86]Ependymoma10/11 (9)--PCR, IHC (TAg)Bergsagel et al. [@CR10]--1/39 (2.6)IHC (TAg)Tabuchi et al., [@CR141], [@CR142]3/3 (100)--PCRLednicky et al. [@CR89]8/11 (73)--PCR, SBMartini et al. [@CR98]0/33--PCRRT-PCREngels et al. [@CR50]Anaplastic ependymoma1/25 (1)--PCRWeggen et al. [@CR149]Anaplastic meningioma1/131 (1)0/131PCRIHC (TAg)Weggen et al. [@CR149]GBM10/30 (33)--PCR, SBMartini et al. [@CR98]0/3--SBKrieg et al. [@CR86]1/7 (14)--D-DHMeinke et al. [@CR101]3/13 (23)--PCRIHC (TAg)Kouhata et al. [@CR85]Medulloblastoma2/6 (33)0/13PCRLednicky et al. [@CR89]5/17 (29)--PCR, SBHuang et al. [@CR70]2/116 (2)0/116PCRIHC (TAg)Weggen et al. [@CR149]0/150/15PCR, SBIHC (TAg)Kim et al. [@CR80]1/2 (50)--SBKrieg et al. [@CR86]Meningioma1/7 (14)--PCR, SBMartini et al. [@CR98]5/16 (31)--SBKrieg et al. [@CR86]sPNET0/50/5PCR, SBIHC (TAg)Kim et al. [@CR80]Abbreviations used: *PCR* polymerase chain reaction, *RT*-*PCR* real-time PCR, *nPCR* nested PCR, *IHC* immunohistochemistry, *SB* Southern blot, *IPPt* immunoprecipitation, *D*-*DH* DNA-DNA rehybridization kinetics, *TAg* T antigen, *Agno* agnoprotien, *GBM* glioblastoma multiforme, *sPNET* supratentorial primary neuroectodermal tumor

BK virus {#Sec11}
--------

First discovered in 1971, the BK virus was originally found in the urine of a renal transplant patient with renal stenosis (Gardner et al. [@CR55]). Similar to JCV, BKV's oncogenicity in experimental animal models and association with human disease, namely hemorrhagic cystitis and polyomavirus nephropathy, has been well-studied and reviewed (Tognon et al. [@CR143]; Fioriti et al. [@CR51]; Yogo et al. [@CR158]; Abend et al. [@CR1]; Jiang et al. [@CR75]). Opposite to JCV, BKV seroprevalence reaches around 90% in children 5 to 9 years and decreases in prevalence with advanced age (Knowles et al. [@CR83]).

As was the case with JCV, BK virus has been detected in a wide variety of primary CNS tumor subtypes as shown in Table [2](#Tab2){ref-type="table"}. BK virus has been detected in highest numbers by PCR in astrocytoma (16/17), ependymoma (10/11), and GBM (28/30) (Martini et al. [@CR98]), while none has been detected in medulloblastoma (0/15; Kim et al. [@CR80]). On the contrary, Arthur et al. were unable to detect BK virus in any of the 75 tumors tested by PCR (Arthur et al. [@CR3]). IHC has not been performed on a large subset of CNS tumors, however, BK virus TAg has been reported in 8/10 glial tumors by RT-PCR (Martini et al. [@CR98]).

SV40 Virus {#Sec12}
----------

The SV40 was first introduced into the human population through preparations of contaminated polio vaccines administered between the years 1955 and 1963. The natural host of SV40 is the rhesus macaque, and its horizontal transmission among humans as well as its causative role in human disease has come under question (Butel et al. [@CR16]; Jasani et al. [@CR72]; Klein et al. [@CR82]; Gazdar et al. [@CR56]; Carbone et al. [@CR18]; Garcea [@CR53]; Garcea and Imperiale [@CR54]; Ahsan and Shah [@CR2]; and Pipas [@CR118]). The seroprevalence of SV40 is estimated to range from 1.3% to 5% in groups of all ages (Knowles et al. [@CR83]). As shown in Table [2](#Tab2){ref-type="table"}, the overall percentage of tumors positive for SV40 by PCR is lower than reported for the other polyomaviruses. The lower-grade tumors (choroid plexus papilloma, astrocytoma, meningioma, ependymoma) tended to be more positive than the higher-grade tumors (GBM, anaplastic ependymoma, medulloblastoma, supratentorial PNET) with little known about T antigen expression by IHC. As with the other polyomaviruses, some groups have failed to detect SV40 DNA by PCR in ependymoma (0/30; Engels et al. [@CR50]) and medulloblastoma (Kim et al. [@CR80]), while Weggen et al. reported minimal detection of SV40 in meningioma (1/131) and medulloblastoma (2/116; Weggen et al. [@CR149]).

Detection of adenovirus in primary CNS malignancies {#Sec13}
===================================================

Adenovirus is a human DNA virus that currently includes 51 serotypes and six species (Benko [@CR9]; Shenk and Horwitz [@CR133]) and has been shown to induce multiple tumors in newborn hamsters including neuroectodermal tumors and medulloblastoma (Yabe et al. [@CR156]; Hohlweg et al. [@CR68]). Kosulin et al. recently screened a series of 538 solid tumors and leukemias/lymphomas for the presence of adenovirus subtypes by real-time PCR and ISH (Kosulin et al. [@CR84]). Adenovirus species were detected by PCR in ependymoma (20/30, species B,D,C), GBM (25/30, species B,D), and oligoastrocytoma (22/30, species B), while none were reported positive in astrocytoma, medulloblastoma, or germinoma. A subset of PCR-positive and PCR-negative samples were confirmed by ISH using adenovirus-specific probes. Among the adenoviral oncogenes detected in this study were E1A, EIB, and E4 ORF-1, the products or which have been shown to exhibit transforming capacity in animal models (White and Cipriani [@CR150]; Shenk and Flint [@CR132]; Javier [@CR74]). A specific role, if any, of adenovirus infection in primary CNS tumors remains unclear since in the same study the authors report 11/20 normal brain harbor adenovirus DNA sequences (Kosulin et al. [@CR84]).

Molecular mechanisms of viral-mediated CNS neuro-oncomodulation {#Sec14}
===============================================================

Alpha herpesviruses {#Sec15}
-------------------

While few studies have been performed to investigate the prevalence of the alpha herpesviruses (HSV-1/2, VZV) in primary CNS tumors, aside from serological studies, this family of herpesviruses has been shown to interact with and regulate the retinoblastoma (Rb) tumor suppressor pathway; a well-characterized pathway involved oncogenesis (Hayward et al. [@CR67]; Hume and Kalejta [@CR71]). As illustrated in Fig. [1](#Fig1){ref-type="fig"}, Rb is a transcriptional co-repressor (along with p107, p130) that regulates cellular proliferation and differentiation. During cellular senescence, the active hyperphosphorylated form of Rb binds to transcription factor E2F to repress transcriptional activity. In HSV-infected cells, Rb is held in its inactive hypophosphorylated state, possibly due to low cyclin-dependent kinase (CdK) activity. HSV-1, in particular, prevents Rb phosphorylation and through mislocalization, keeps CdK inactive. In the case of VZV, Rb and p107 remain unphosphorylated, in spite of normal CdK activity. One report demonstrated that HSV-2-infected cells induced Rb phosphorylation (Hossain et al. [@CR69]). However, since many of the in vitro studies of HSV-induced hypophosphorylation of Rb was performed in cycling cells, little is known about the effects of latent infection on cellular growth and differentiation in either CNS tumor cell lines or actual disease. Fig. 1Molecular mechanisms of CNS neuro-oncomodulation. The known proliferative molecular mechanisms of herpesvirus and polyomavirus infections on promoting gene expression, inhibition of apoptosis, and enhancing cell motility are shown (*black arrows*). In general, five major signaling pathways converge to promote oncogenesis for both families of viruses (*green arrows*), namely NOTCH/WNT, receptor tyrosine kinase RTK (*EGFR*/*PDGFR*), telomerase (*Tel*), retinoblastoma protein-E2F, and P53 pathways as described in the text

Beta herpesviruses (CMV, HHV-6, and HHV-7) {#Sec16}
------------------------------------------

CMV is perhaps the most well-studied of the herpesviruses with regards to potential molecular mechanisms of neuro-oncogenesis. In particular, the term oncomodulation has been coined to describe how this virus could infect a tumor cell and increase its already malignant potential (Cinatl et al. [@CR22]; Cinatl et al. [@CR25][@CR26]; Michaelis et al. [@CR103]). With regard to oncomodulation in the CNS or neuro-oncomodulation, CMV infection has been shown to modify key molecular oncologic pathways including apoptosis, cell migration, angiogenesis, telomerase activity, and Rb tumor suppressor modulation (Michaelis et al. [@CR103]) as outlined in Fig. [1](#Fig1){ref-type="fig"}. In contrast to the alphaherpesviruses, CMV induces a hyperphosphorylation of Rb following infection of senescent cells (Jault et al. [@CR73]) by activating cyclin E and cyclin-B-dependent kinases. As a consequence of the hyperphosphorylation of Rb, E2F response genes are highly expressed, perhaps due to interaction with CMV immediate early protein 2 (Song and Stinski [@CR137]).

In terms of apoptosis, CMV infection has been shown to prevent death in cancer cells (Michealis et al. Michaelis et al. [@CR102]) through expression of numerous anti-apoptotic proteins (Goldmacher [@CR58]). The CMV UL36 has been shown to inhibit Fas-mediated apoptosis via caspase 8 binding (Skaletskaya et al. [@CR136]). CMV UL123/124 proteins have been shown to inhibit apoptosis by activating the PI3 kinase activity (Yu and Alwine [@CR160]). CMV UL37 inhibits apoptosis by disrupting mitochondrial networks through an uncharacterized mechanism (McCormick et al. [@CR99]). In addition to apoptotic mechanisms, CMV infection has been shown to increase smooth muscle cell migration, perhaps by beta-1 alpha-5 integrin-mediated binding to endothelin (Scholz et al. [@CR131]) or in the case of glial cells, by an increase in AKT kinase activity (Cobbs et al. [@CR29], [@CR30]). CMV may also promote oncogenesis by increasing telomerase activity, since human diploid cells and malignant cells infected with CMV show increased telomerase activity by stimulating hTERT gene expression (Straat et al. [@CR140]).

In terms of angiogenesis, CMV-infected glial cell lines show downregulation of many negative regulators of angiogenesis including thrombospondin 1 and 2 (Cinatl et al. [@CR23], [@CR24]). Tumor necrosis alpha, a proinflammatory cytokine known to stimulate angiogenic factors in gliomas (VEGF, IL8; Nabors et al. [@CR107]), has also been reportedly increased following CMV infection of GBM cell lines (Baillie et al. [@CR4]). Additionally, CMV has been shown to induce CD40 expression on the surface of infected cells, which, upon binding to CD40 ligand, results in increased VEGF production (Maisch et al. [@CR96]). More recently, CMV has been shown to interact with the epidermal growth factor receptor (Wang et al. [@CR148]) and platelet-derived growth factor receptor alpha (Soroceanu et al. [@CR138]), two members of the receptor tyrosine kinase (RTK) family of receptors known to be upregulated in a number of primary CNS malignancies. While there is still some debate about the exact putative receptor of CMV-mediated entry and pathogenesis, modulation of either or both of the RTK pathways would help to support a role of CMV in neurooncogenesis. An indirect role for HCMV in neuro-oncomodulation is also possible, as HCMV has been shown to activate critical cell proliferative pathways in the absence of viral gene expression (Shibutani et al. [@CR134], Boyle et al. [@CR15], Johnson et al. [@CR76], [@CR77], [@CR78]).

Potential neuro-oncomodulatory mechanisms of chronic HHV-6 and HHV-7 infected CNS-derived cells are much less well-understood. Since HHV-6 has been shown to be chromosomally integrated in a subset of the population detected at birth (Hall et al. [@CR62]), the role of chronic persistent infection on cellular proliferative mechanisms is not clear. One potential candidate is the HHV-6 viral oncogene that has been detected in human GBM by PCR and directly interacts with P53 (Kashanchi et al. [@CR79]).

Gamma herpesviruses {#Sec17}
-------------------

Although the gammaherpesviral infections have been reported predominantly in B cells, both EBV and HHV-8 are oncogenic viruses which directly interact with elements of two key regulatory pathways in neuro-oncogenesis, namely Notch and WNT (Fig. [1](#Fig1){ref-type="fig"}; Hayward et al. [@CR67]). The Notch pathway is composed of a subfamily of receptors (Notch1-4) and ligands (Jagged1,2, Delta-like 1,3,4,), that upon binding of ligand to receptor results in cleavage of the intracellular Notch receptor domain (Notch IC). Notch IC then binds to CSL, a DNA binding protein and nuclear effector of the Notch pathway, displacing it and thus promoting transcription. EBV protein EBNA2 specifically interacts with CSL stimulating cellular proliferation and is necessary for the establishment of viral latency (Hayward et al. [@CR67]). Similar to EBV, HHV-8 also interacts with CSL, but this interaction is critical for lytic infection as opposed to latency.

The WNT pathway is a complex pathway involving cell surface receptors, cytosolic complexes, and nuclear effectors, all designed to regulate cellular proliferation and differentiation. The WNT family of glycoproteins binds to the frizzled family of receptors and co-receptors (Lrp5/8) that ultimately results in the regulation of beta catenin, the nuclear effector of the WNT pathway, whose expression has been positively associated with a favorable prognosis in a number of CNS malignancies (Ellison et al. [@CR49]; Rogers et al. [@CR124]). The availability of nuclear beta catenin is dependent on the regulation of its phosphorylation by an extensive complex composed in part by APC, CKI, and GSK-3 (Fig. [1](#Fig1){ref-type="fig"}). In the phosphorylated state (promoted by both CKI and GSK-3), beta catenin is targeted for intracytosolic destruction by proteosome degradation. In the active non-phosphorylated state, beta catenin is responsible for the transcription of numerous neuroonco-proliferative genes including C-myc, N-myc, cyclin C1, MMP-7, VEGF, surviving, axin 2, and c-Jun, among others (Hayward [@CR66]). HHV-8 infection results in high cytoplasmic levels of beta catenin, due to its interaction with the HHV-8 latency-associated nuclear antigen (LANA). LANA causes dysregulation of beta catenin by inducing a nuclear translocation of GSK-3, essentially saving beta catenin from degradation. EBV similarly stabilizes beta catenin, through interactions with the EBV protein LMP-1, via unknown mechanisms.

The gammaherpesviruses also have regulatory interactions with the Rb pathway as per the other herpesviruses. EBV encodes many proteins (Z,R,LMP-1,EBNA-2,3C,S) that can lead to Rb phosphorylation by activation of cellular Cdk's or through direct phosphorylation by viral encoded kinases (Hayward et al. [@CR67], [@CR66]). HHV-8 can similarly activate the Rb pathway by disruption of Rb--E2F interactions mediated by LANA, v cyclin or HHV-8 ORF36-encoded proteins (Rajcani and Kudelova [@CR121]; Hamza et al. [@CR63]).

Polyomaviruses (BKV, JCV, and SV40) {#Sec18}
-----------------------------------

Each of the polyomaviruses share similar oncogenic mechanisms via interactions between the two viral T antigens (small T-tAG, large T-TAG) and key cellular regulatory pathways such as P53 and Rb as illustrated in Fig. [1](#Fig1){ref-type="fig"} (Croul et al. [@CR34]; Barbanti-Brodano et al. [@CR8]; Lee and Langhoff [@CR90]). The large TAG is the major oncogenic antigen and acts by directly increasing cell proliferation, inhibiting apoptosis, and damaging DNA. TAG has been shown to bind to unphosphorylated Rb, causing release of E2F and subsequent cell cycle progression. Alternatively, TAG can modify Rb degradation pathways through binding of molecular chaperone protein hsp70 (Lee and Langhoff [@CR90]). TAG has been shown to bind to P53 tumor suppressor protein, resulting in uncontrolled cellular proliferation and blockage of apoptosis (Harris et al. [@CR64]). This may work through inhibition of p21/WAG-1, a stabilizing complex upstream of cyclin dependent kinase-cdK. Alternatively, TAG can also affect P53-mediated transcription without directly binding to P53 (Rushton et al [@CR127]). Lastly, TAG can promote oncogenesis by causing direct chromosomal damage in cultured human cells infected with BK and SV40 viruses (Ray et al. [@CR122]; Stewart and Bacchetti [@CR139]; Trabanelli et al. [@CR144]), or by interfering with topoisomerase I and helicase activities (Simmons et al. [@CR135]; Dean et al. [@CR40]).

Polyomavirus small t antigen (tAG) promotes cell division through interaction with PP2A and phosphatidylinositol 3-kinase regulatory pathways (Barbanti-Brodano et al. [@CR8]; Fig. [1](#Fig1){ref-type="fig"}). tAG has been shown to inhibit PP2A function, a major regulator of the WNT/beta catenin pathway, by directly binding to both regulatory and catalytic PP2A domains (Garcea and Imperiale [@CR54]; Barbanti-Bordano et al. [@CR7], [@CR8]). As a consequence, the WNT pathway is inhibited and beta catenin is free to translocate to the nucleus to stimulate gene expression. In addition, PP2A inactivation by tAG affects cytoskeletal integrity and promotes tumor migration in epithelial cells (Nunbhakdi-Craig et al. [@CR110]) infected with SV40 virus.

Discussion {#Sec19}
==========

The concept of viral-associated CNS malignancy has been met with appropriate skepticism from the scientific community. The major difficulties in establishing a more widespread acceptance of the concept of viral-mediated CNS disease are due in part to: lack of reproducible findings among researchers regarding viral detection in CNS tumors, paucity of animal model systems to study direct viral mechanisms of neuro-oncogenesis, high seroprevalence among controls and tumors alike, lack of stable detection of viruses in long-term cultures of human CNS tumors, and inability to induce transformation in non-cancerous primary human CNS-derived cell lines.

Among potential possibilities to explain discrepancies of viral detection frequencies in CNS tumors between researchers includes tissue integrity, fixation conditions, tissue thickness, antibody dilution, incubation parameters, and PCR methodologies (Scheurer et al. [@CR130]). For example, in the case of BKV and JCV, ultrasensitive nested PCR has been shown to have a sensitivity of ten genomes per viral copy (Bogdanovic et al. [@CR11]). In the case of HHV-6, up to fivefold difference in detection sensitivity has been reported in a multicenter comparison among various PCR methodologies including nested PCR (Flamand et al. [@CR52]). Unfortunately, in many cases, specific viral load quantification has not been performed with regard to CNS clinic specimens and the theoretical copy number sufficient to modify disease known. Another explanation for discrepancies of viral detection frequency is geographic distributions of latent CNS infections. However, given the widespread seropositivity worldwide, this seems less likely and difficult to prove unless viral genomic sequences are studied for region-specific polymorphisms. Since the CNS is a potential reservoir for many latent neurotropic viruses, it is difficult to assign causation by detection alone. Unfortunately, there has been no investigation of the frequency of viral genomic or antigen detection in a large diverse cohort of normal brain by serial anatomic sectioning to assess for anatomic tropism. This information is paramount to determine whether viral associations with CNS tumors are related to specific viral anatomic or cellular tropism versus a more global reactivation phenomenon associated with malignancy in general. For instance, in the case of JCV, it has been recently reported that JCV genomic segments but not proteins are present normal-appearing brain in a small series (Perez-Liz et al. [@CR116]). Finding differences in genomic quantity or protein expression between CNS tumors and non-tumor CNS controls is critical in the establishment of a potential link between chronic viral infection and malignancy. Since many of the viruses establish latency in cells of hematopoetic origin, it is difficult without ISH or IHC methodologies to accurately confirm that positive PCR studies are exclusively of CNS origin. It is possible that propagation of viral macromolecules into the CNS could come via lymphocytes as suggested in the case of CMV by the high CMV detection in sera of patients with GBM (Mitchell et al. [@CR106]).

In terms of animal models of neuro-oncogenesis BKV, SV40, and JC have all been shown to induce a number of CNS tumors in animal models, many of them correlating with the corresponding histological subtypes detected in human primary CNS tumors. For instance, BKV has been shown to induce ependymoma and choroid plexus papilloma in hamsters (Barbanti-Brodano et al. [@CR5], [@CR7]; Tognon et al. [@CR143]) and has been detected in the corresponding subtypes in humans with high frequency (Negrini et al. [@CR108]; Martini et al. [@CR98]). Using the same animal model system, JCV inoculated intra-cerebrally induced mostly medulloblastoma in greater than 80% (Walker et al. [@CR147]), suggesting that there may be a neuro-oncologic viral tropism. To date, JCV is the only polyomavirus able to induce CNS tumors in non-human primates. Following injection of JCV in squirrel monkeys, astrocytic tumors developed following a latency of 14--36 months (London et al [@CR92], [@CR93]) and contained both integrated JCV DNA and expressed TAg protein (Miller et al. [@CR105]; Major et al. [@CR97]). These observations correlate with the detection of JCV DNA and TAg in human tumors that shows a predominance of JCV in CNS tumors of glial origin (Table [2](#Tab2){ref-type="table"}). In the case of the herpesviruses, it is unclear whether the lack of malignant transformation in cell culture or in animal models is due to technical aspects of host infectivity versus a true lack of intrinsic neuro-oncogenic properties of viral infection. However, this does not rule out potential neuro-oncomodulatory mechanisms that may be contributing to pathogenesis of disease through epigenetic mechanisms.

The JCV primate data, while not conclusive for a role in human CNS tumorigenesis, does provide important insight into the potential time course and mechanisms of neuro-oncomodulation. The relatively short induction latency period before tumor formation in squirrel monkeys, when extracted to human lifespan is roughly between 10--20 years, suggestive of a chronic viral persistence as opposed to primary infection. In the case of acute infection, one would expect a sharp contrast in viral detection frequencies between adult and childhood CNS tumors, which has not been reported for either polyomaviruses or herpesviruses. Although, given the very high seroprevalence reported for both viruses at an early age, it would be very difficult to associate acute infection with malignancy based on epidemiology alone, making the concept of viral persistence more attractive in the case of neuro-oncomodulation as opposed to neuro-oncogenesis. In order for a virus to remain persistent in the CNS, it must replicate without killing the host and avoid the immunoprotective mechanisms designed to remove it (Oldstone [@CR113]). It is possible these exact mechanisms used to avoid detection, may promote neuro-oncomodulation through common molecular pathways (Fig. [1](#Fig1){ref-type="fig"}). It is also conceivable that viral integrative mechanisms may promote oncogenesis alone in the absence of viral protein expression by insertion within key genomic regions.

A specific role of herpesviruses in primary CNS tumors remains to be determined and is met with similar skepticism as the polyomaviruses (Miller [@CR104]). In the case of CMV, the theoretical neuro-oncogenic mechanisms are in question largely because of its inability to transform normal human cells in culture. From a more practical standpoint, the variance in detection frequency among researchers and the high seroprevalence makes it difficult to establish a firm association. One way to circumvent these critiques and demonstrate a functional role for CMV and other viruses in CNS tumors is to study the effect of treatment on disease. One example of this is the detection of CD8+ T cells in a GBM patient that were specific for the CMV protein pp65 following vaccination of autologous tumor lysate (Prins et al. [@CR120]). Other clues to CMV's role are currently being studied in two clinical trials in patients with GBM treated with valganciclovir and CMV pp-65-modified dendritic cell vaccines ([www.clinicaltrials.gov](http://www.clinicaltrials.gov)), the results of which are pending. While negative results do not necessarily exclude a role of viral infection in CNS malignancy for a number of reasons, an improvement in clinical outcome is supportive of such a hypothesis. Although even a positive correlation between treatment and survival could be explained by a secondary effect of treatment alone unrelated to viral infection.

In order establish a more widespread support for the role of viruses in either neuro-oncogenesis or neuro-oncomulation, much work needs to be done. First, there must be a more widespread cooperative validation of the multitude of PCR, ISH, and IHC techniques used in the detection of viral macromolecules. More importantly, the differences in viral detection among researchers must be more concretely explained through rigorous experimental approaches. Second, a better understanding of both regional and anatomic viral tropisms in normal brain of varying ages needs to be determined. The early and late effects of viral infection in CNS-derived cell lines would provide potential mechanisms of disease that could potentially be extrapolated to human CNS disease. Lastly, the design and implementation of new clinical trials directed at either targeting specific viral infections or modifying CNS neuroimmunity in favor of a cell-mediated or humoral-specific antiviral response is needed. Ultimately, a more thorough understanding of the neuroimmunology of CNS tumors is necessary to move the emerging field of neuro-viro-oncology forward.
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